在Mirikizumab (STORM) 研究中对最佳反应进行治疗序列化:对治疗耐药性性结肠炎患者进行的第三级转诊中心研究
Alica Kubesch1, Raul Lande1, Anna Leutgöb1
1Goethe University Frankfurt, University Hospital, Medical Clinic 1, Frankfurt, Germany.
米里基祖马布在先前用生物药物治疗的性结肠炎 (UC) 患者中显示出良好的短期和长期疗效. 之前的抗瘤坏死因子 (TNF) 治疗与更好的生化缓解结果有关.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 优化药物测序对于性结肠炎 (UC) 管理至关重要.
- 对于先前生物暴露的患者,特别是抗瘤亡因子 (TNF) 药物的mirikizumab反应的现实数据是有限的.
- 这项研究评估了mirikizumab在UC患者的疗效,这些患者对先前的生物疗法不耐药.
研究的目的:
- 评估生物耐药性性结肠炎 (UC) 患者对mirikizumab的治疗反应.
- 根据先前的生物暴露,比较治疗结果,包括抗TNF和Janus激酶抑制剂 (JAKi) 治疗.
- 评估短期 (12周) 和长期 (长达80周) 的临床和生化缓解率.
主要方法:
- 从2023年7月到2025年5月,连续52名UC患者接受了mirikizumab治疗的回顾性分析.
- 主要终点:12周临床缓解.
- 二级终点:临床和生化缓解在24-50周和60-80周.
主要成果:
- 观察到12周的临床缓解率为67.3% (35/52).
- 治疗持续时间与临床和生化缓解有显著的相关性.
- 之前的抗TNF治疗对生物化学缓解产生了积极的影响 (OR=3.489,p=0.021),而之前的JAKi治疗对临床缓解产生了负面影响 (OR=0.19,p=0.019).
结论:
- 米里基祖马布在UC患者中表现出有利的短期和长期疗效,这些患者之前有过生物治疗史.
- 以前接受过抗TNF治疗的患者经历了更好的生化缓解结果.
- 这些发现支持mirikizumab作为在重度预治疗UC人群中有效的选择.
更多相关视频
05:41Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
